Unlocking the Potential of Breakthroughs in NSCLC Therapeutic Approaches
| Target Professions: | DO, MD, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Oncology |
| Credits Available: | 5.0 AMA PRA Category 1 Credits™ |
The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.
CME/CE Accreditation Information
Itinerary
PART ONE
Answer the following questions to assess your knowledge on the management of advanced NSCLC with ADCs.
This module discusses the role of TROP2-directed ADCs in treating patients with advanced NSCLC and adverse events associated with TROP2-directed ADCs.
This module discusses the role of HER2 mutations in NSCLC, optimal testing methodologies to detect these alterations, appropriate utilization of HER2-targeted therapies in NSCLC, and strategies to optimize treatment with these agents.
This module discusses the role of HER3-directed ADCs in treating patients with advanced EGFR-mutant NSCLC and adverse events associated with HER3-directed ADCs.
Now that you have reviewed the self-study modules, answer the following questions to assess your knowledge on the management of advanced NSCLC with ADCs.
The group will discuss key points from each of the preceding modules, as well as group challenge submissions and general comments.
PART TWO
This activity features a 62-year-old Asian woman with EGFR-mutated advanced NSCLC. She had a partial response to first-line osimertinib, however, her disease progressed after 10 months. This challenge examines strategies to initiate second-line therapy.
This activity features a 60-year-old woman who presents with HER2-mutant metastatic nonsquamous NSCLC. Clinical implications of HER2 on NSCLC, how to select therapy for HER2-mutant NSCLC, and how to manage treatment-emergent adverse events are explored.
This activity features a hypothetical case vignette to serve as the focal point for a discussion on the potential use of a HER3-directed ADC as third-line therapy in a patient with metastatic NSCLC.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the management of patients with metastatic NSCLC using an antibody-drug conjugate.
The group will discuss their action plans and barriers to implementation while receiving real-time feedback from the group leader and other group members.
Interested in becoming a Group Leader?
Group leaders should be highly proficient in the management and treatment of metastatic NSCLC and with working in collaboration with other healthcare professionals. Group leaders include clinicians involved in specialized care for patients with NSCLC (such as academic-based clinicians), clinical research studies related to the treatment of advanced NSCLC with antibody-drug conjugates (ADCs), and associated clinical teaching. Apply Now
